Cat. #151781
MCF7aro Let-R Cell Line
Cat. #: 151781
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 8-10 weeks
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Tumour line
£800.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Marie McIlroy
Institute: Royal College of Surgeons Ireland (RCSI)
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: MCF7aro Let-R Cell Line
- Cancer: Breast cancer
- Cancers detailed: Breast cancer
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: MCF7
- Organism: Human
- Tissue: Breast
- Disease: Cancer
- Model: Tumour line
- Conditional: Yes
- Description: MCF7aro Let-R Cell Line is a human cell line model of aromatase inhibitor resistant breast cancer.
- Production details: Letrozole (aromatase inhibitor) sensitive cells (MCF-7aro) were developed by stable transfection of the aromatase gene (CYP19); Letrozole-resistant cells (MCF-7aro Let-R) were created by long-term treatment of aromatase-expressing MCF7 cells (MCF7aro) with letrozole.
- Biosafety level: 1
- Cellosaurus id: CVCL_W348
Target Details
- Target: Aromatase expressing, Letrozole resistant
Handling
- Format: Frozen
- Growth medium: They are cultured in phenol red free Eagle's Minimum Essential Medium (Phenol-red free MEM) (Sigma Aldrich), 10% charcoal dextran stripped FCS (CDS-FCS), 1% Pen-Strep (Sigma Aldrich), 2 mM L-Glutamine (Sigma Aldrich) and 200 ??g/ml G418 disulfate salt (Geneticin) (Sigma Aldrich), 2.5-8 M androstenedione and 10-6 M letrozole.
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
References
- Cellosaurus MCF-7aro Let-R (CVCL_W348)
- O'Hara et al. 2012. Clin Cancer Res. 18(12):3305-15. PMID: 22550166.
- AIB1:ERa transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
- McIlroy et al. 2010. Cancer Res. 70(4):1585-94. PMID: 20145129.
- Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
